Dimethyl fumarate, a small molecule drug for psoriasis, inhibits Nuclear Factor-kappaB and reduces myocardial infarct size in rats
Persistent Nuclear Factor-kappaB (NF-kappaB) activation is hypothesized to contribute to myocardial injuries following ischemia-reperfusion. Because inhibition or control of NF-kappaB signaling in the heart probably confers cardioprotection, we determined the potency of the NF-kappaB inhibitor dimet...
Saved in:
Published in | European journal of pharmacology Vol. 586; no. 1-3; pp. 251 - 258 |
---|---|
Main Authors | , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Netherlands
31.05.2008
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Persistent Nuclear Factor-kappaB (NF-kappaB) activation is hypothesized to contribute to myocardial injuries following ischemia-reperfusion. Because inhibition or control of NF-kappaB signaling in the heart probably confers cardioprotection, we determined the potency of the NF-kappaB inhibitor dimethyl fumarate (DMF) in cardiovascular cells, and determined whether administration of DMF translates into beneficial effects in an animal model of myocardial infarction. In rat heart endothelial cells (RHEC), we analysed inhibitory effects of DMF on NF-kappaB using shift assay and immunohistofluorescence. In in vivo experiments, male Sprague Dawley rats undergoing left coronary artery occlusion for 45 min received either DMF (10 mg/kg body weight) or vehicle 90 min before ischemia as well as immediately before ischemia. After 120 min of reperfusion, the hearts were stained with phthalocyanine blue dye and triphenyltetrazolium chloride. Additionally, acute hemodynamic and electrophysiologic effects of DMF were determined in dose-response experiments in isolated perfused rat hearts. DMF inhibited TNF-alpha-induced nuclear entry of NF-kappaB in RHEC. In in vivo experiments, myocardial infarct size was significantly smaller in rats that had received DMF (20.7%+/-9.7% in % of risk area; n=17) than in control rats (28.2%+/-6.2%; n=15). Dose-response experiments in isolated perfused rat hearts excluded acute hemodynamic or electrophysiologic effects as mechanisms for the effects of DMF. DMF inhibits nuclear entry of NF-kappaB in RHEC and reduces myocardial infarct size after ischemia and reperfusion in rats in vivo. There was no indication that the beneficial effects of DMF were due to acute hemodynamic or electrophysiologic influences. |
---|---|
AbstractList | Persistent Nuclear Factor-kappaB (NF-kappaB) activation is hypothesized to contribute to myocardial injuries following ischemia-reperfusion. Because inhibition or control of NF-kappaB signaling in the heart probably confers cardioprotection, we determined the potency of the NF-kappaB inhibitor dimethyl fumarate (DMF) in cardiovascular cells, and determined whether administration of DMF translates into beneficial effects in an animal model of myocardial infarction. In rat heart endothelial cells (RHEC), we analysed inhibitory effects of DMF on NF-kappaB using shift assay and immunohistofluorescence. In in vivo experiments, male Sprague Dawley rats undergoing left coronary artery occlusion for 45 min received either DMF (10 mg/kg body weight) or vehicle 90 min before ischemia as well as immediately before ischemia. After 120 min of reperfusion, the hearts were stained with phthalocyanine blue dye and triphenyltetrazolium chloride. Additionally, acute hemodynamic and electrophysiologic effects of DMF were determined in dose-response experiments in isolated perfused rat hearts. DMF inhibited TNF-alpha-induced nuclear entry of NF-kappaB in RHEC. In in vivo experiments, myocardial infarct size was significantly smaller in rats that had received DMF (20.7%+/-9.7% in % of risk area; n=17) than in control rats (28.2%+/-6.2%; n=15). Dose-response experiments in isolated perfused rat hearts excluded acute hemodynamic or electrophysiologic effects as mechanisms for the effects of DMF. DMF inhibits nuclear entry of NF-kappaB in RHEC and reduces myocardial infarct size after ischemia and reperfusion in rats in vivo. There was no indication that the beneficial effects of DMF were due to acute hemodynamic or electrophysiologic influences. |
Author | Barbosa, Vania Zaugg, Christian E Fasler-Kan, Elizaveta John, Dietlinde Meili-Butz, Silvia Butz, Nicole Buser, Peter T Niermann, Thomas Brink, Marijke |
Author_xml | – sequence: 1 givenname: Silvia surname: Meili-Butz fullname: Meili-Butz, Silvia email: Silvia.Meili@unibas.ch organization: University Hospital Basel, Department of Research, Cardiobiology Laboratories, Switzerland. Silvia.Meili@unibas.ch – sequence: 2 givenname: Thomas surname: Niermann fullname: Niermann, Thomas – sequence: 3 givenname: Elizaveta surname: Fasler-Kan fullname: Fasler-Kan, Elizaveta – sequence: 4 givenname: Vania surname: Barbosa fullname: Barbosa, Vania – sequence: 5 givenname: Nicole surname: Butz fullname: Butz, Nicole – sequence: 6 givenname: Dietlinde surname: John fullname: John, Dietlinde – sequence: 7 givenname: Marijke surname: Brink fullname: Brink, Marijke – sequence: 8 givenname: Peter T surname: Buser fullname: Buser, Peter T – sequence: 9 givenname: Christian E surname: Zaugg fullname: Zaugg, Christian E |
BackLink | https://www.ncbi.nlm.nih.gov/pubmed/18405893$$D View this record in MEDLINE/PubMed |
BookMark | eNo1kD1PwzAYhD0U0Q_4Bwh5YmrC6zhu4hEKBaQKlu7VG-cNdXE-sJOhjPxyIgHT6aTn7qSbs0nTNsTYlYBYgFjdHmM6dgf0cQKQx5DEIPMJmwGINEq01lM2D-EIAEon6pxNRZ6CyrWcse8HW1N_ODleDTV67GnJkYcaneN168gMjnjph3detZ53ofUWgw1LbpuDLWwf-OtgHKHnGzR966MP7Dq859iU3FM5GAq8PrUGfWnRjakKvel5sF80Gj4Ohgt2VqELdPmnC7bbPO7Wz9H27ellfbeNOpXKiBJjZClyZVBnBnRCq7SC1YoKzPKslEZCLkinErRSIhcpZcYUUiiVYVVAJRfs5re28-3nQKHf1zYYcg4baoewzyBTQqtkBK__wKGoqdx33o7PnPb_p8kflYdyFQ |
ContentType | Journal Article |
DBID | CGR CUY CVF ECM EIF NPM 7X8 |
DOI | 10.1016/j.ejphar.2008.02.038 |
DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
DatabaseTitleList | MEDLINE - Academic MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Pharmacy, Therapeutics, & Pharmacology |
EndPage | 258 |
ExternalDocumentID | 18405893 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- --K --M -~X .55 .~1 0R~ 1B1 1RT 1~. 1~5 4.4 457 4G. 53G 5GY 5RE 5VS 7-5 71M 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAXKI AAXLA AAXUO ABCQJ ABFNM ABFRF ABJNI ABMAC ABXDB ABZDS ACDAQ ACGFO ACGFS ACIUM ACRLP ADBBV ADEZE ADMUD AEBSH AEFWE AEKER AENEX AFKWA AFTJW AFXIZ AGUBO AGWIK AGYEJ AIEXJ AIKHN AITUG AJOXV AKRWK ALCLG ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ AXJTR BKOJK BLXMC C45 CGR CS3 CUY CVF DU5 EBS ECM EFJIC EIF EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN G-Q HMQ HZ~ IHE J1W K-O KOM L7B M2V M34 M41 MO0 MOBAO N9A NPM O-L O9- OAUVE OGGZJ OVD OZT P-9 P2P PC. Q38 RIG ROL RPZ SDF SDG SDP SES SPCBC SSN SSP T5K TEORI X7M ~G- 7X8 |
ID | FETCH-LOGICAL-p543-e2cc3d185ca97c092e64f066eba787d3c3081e94309551814e7ccb31557afb0f3 |
ISSN | 0014-2999 |
IngestDate | Sat Aug 17 01:16:24 EDT 2024 Sat Sep 28 07:57:12 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1-3 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-p543-e2cc3d185ca97c092e64f066eba787d3c3081e94309551814e7ccb31557afb0f3 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
PMID | 18405893 |
PQID | 70751952 |
PQPubID | 23479 |
PageCount | 8 |
ParticipantIDs | proquest_miscellaneous_70751952 pubmed_primary_18405893 |
PublicationCentury | 2000 |
PublicationDate | 2008-May-31 20080531 |
PublicationDateYYYYMMDD | 2008-05-31 |
PublicationDate_xml | – month: 05 year: 2008 text: 2008-May-31 day: 31 |
PublicationDecade | 2000 |
PublicationPlace | Netherlands |
PublicationPlace_xml | – name: Netherlands |
PublicationTitle | European journal of pharmacology |
PublicationTitleAlternate | Eur J Pharmacol |
PublicationYear | 2008 |
SSID | ssj0005925 |
Score | 1.9074328 |
Snippet | Persistent Nuclear Factor-kappaB (NF-kappaB) activation is hypothesized to contribute to myocardial injuries following ischemia-reperfusion. Because inhibition... |
SourceID | proquest pubmed |
SourceType | Aggregation Database Index Database |
StartPage | 251 |
SubjectTerms | Animals Dermatologic Agents - therapeutic use Dimethyl Fumarate Electrocardiography - drug effects Electrophoretic Mobility Shift Assay Electrophysiology Endothelial Cells - drug effects Endothelial Cells - pathology Fluorescent Antibody Technique Fumarates - therapeutic use Heart Rate - drug effects In Vitro Techniques Male Myocardial Infarction - drug therapy Myocardial Infarction - pathology Myocardial Reperfusion Injury - pathology Myocardium - cytology Myocardium - pathology NF-kappa B - antagonists & inhibitors Nuclear Proteins - metabolism Psoriasis - drug therapy Rats Rats, Sprague-Dawley |
Title | Dimethyl fumarate, a small molecule drug for psoriasis, inhibits Nuclear Factor-kappaB and reduces myocardial infarct size in rats |
URI | https://www.ncbi.nlm.nih.gov/pubmed/18405893 https://search.proquest.com/docview/70751952 |
Volume | 586 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1Lb9NAEF6FcuGCKM9CgT2gXpyNEj9i75FCowpKqISLcrPW613VJXEsO6mUHjjwN_izzD4cu6IVj4sVW4q98XzZ-XZ25huE3ohoKIMgdIlgbEh8mY0JlZkk2YiKgErmZ0IVOH-ajo_P_A-zYNbr_exkLa1X6YBf3VhX8j9WhWtgV1Ul-w-W3d4ULsBnsC8cwcJw_Csbv89VA-jN3JEqUZqZTnfMqRdqv3lhGt8KJ6vWJlmyrJcwqNqoCuTFeZ6qXYOpUjRmlTPRnXfIN1aW7NCknStZV1E7iw04vEpXmMCo4Z-xcur8SquNwEPrW4P7luiWrTp2m3Is8nlODte6m6zzJZ9f5lv_MM2VtzC8upO_pBUj67moyEcTtNUZaZdi1YYUWJUua82Gv7LC3rCJaETNZnw7S498Am6SdmfpwCpmWzgSrzvrWs1aYc-iG32DCVNcDMSF-t02jdYdDI26zHUp7unnZHJ2cpLER7P4DrrrhjRQK_vB907-EHVtewwz2KYuUycP_v6M21cwmsnED9B9uwTBbw2edlFPFA_Rwamx0qaP47Ykr-7jA3zasd8j9KMBHW5A18cMa8jhBnJYQQ4D5PAWcn3cAA5bwOFrgMMAOGwBh1vAYQs4rAAHJ1gB7jGKJ0fxu2NiG3mQMvA9IlzOvQyIIWc05EPqirEvgeqKlIG7yDzuAS8Vqg8AVfqAI1-EnKceMN2QyXQovSdop1gW4hnCaeBlinP6I8l94Jo08qJxFvEQCJjkku2h181bTmCeVJtfrBDLdZ2EwI1HNHD30FPz8pPSyLkkKsYRAG1__sfvvkD3Wrzuo51VtRYvgZOu0lcaG78AxOaVcg |
link.rule.ids | 315,786,790,27957,27958 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Dimethyl+fumarate%2C+a+small+molecule+drug+for+psoriasis%2C+inhibits+Nuclear+Factor-kappaB+and+reduces+myocardial+infarct+size+in+rats&rft.jtitle=European+journal+of+pharmacology&rft.au=Meili-Butz%2C+Silvia&rft.au=Niermann%2C+Thomas&rft.au=Fasler-Kan%2C+Elizaveta&rft.au=Barbosa%2C+Vania&rft.date=2008-05-31&rft.issn=0014-2999&rft.volume=586&rft.issue=1-3&rft.spage=251&rft.epage=258&rft_id=info:doi/10.1016%2Fj.ejphar.2008.02.038&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0014-2999&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0014-2999&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0014-2999&client=summon |